SCHEMBL4309787

SCHEMBL4309787

CCc1cc(C(=O)C(=O)c2ccc(F)c(Br)c2)ccc1OC(F)F

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PDE4A P27815 7/20 0.36
PDE4B Q07343 7/20 0.36
PDE4C Q08493 7/20 0.36
PDE4D Q08499 7/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 1/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.35
KCNH2 Q12809 1/20 0.35
GRIN2B Q13224 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315649 0.88 L3MBTL1 (0.38) L3MBTL1CES2CES1PDE4APDE4B
SCHEMBL4313438 0.84 CES2 (0.40) CES2CES1PDE4APDE4BPDE4C
SCHEMBL4309529 0.83 CES2 (0.39) L3MBTL1CES2CES1PDE4APDE4B
SCHEMBL4308482 0.83 L3MBTL1 (0.42) L3MBTL1PDE4APDE4BPDE4CPDE4D
SCHEMBL4312454 0.81 REN (0.42) L3MBTL1CES2CES1PDE4APDE4B
SCHEMBL4309731 0.81 TTR (0.39) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL4308383 0.80 BACE1 (0.41) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL27779808 0.79 CYP1A2 (0.39) L3MBTL1PDE4APDE4BPDE4CPDE4D
SCHEMBL2791543 0.78 ALOX15 (0.51) L3MBTL1CES2CES1ALDH1A1LMNA
SCHEMBL4306215 0.78 L3MBTL1 (0.35) L3MBTL1ALDH1A1MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP L3MBTL1 3592/4885CES2 2959/4885CES1 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.